Atrium Doses First Patient in Phase 1/2 ATR 1072 PRKAG2 Trial
San Diego – October 29, 2026 -- Atrium Therapeutics (Nasdaq: RNA) has dosed the first patient in Corventis, a Phase 1/2 trial of ATR 1072 in PRKAG2 syndrome, and expects initial proof-of-concept data in the second half of 2027.
Corventis will enroll about 37 participants in two parts
The open-label, multicenter study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of ATR 1072. Part A uses multiple ascending dose cohorts to characterize safety and support dose selection. Part B is a single-arm expansion cohort at the recommended Phase 2 dose, assessing efficacy trends in cardiac structure and function.
The primary endpoint is the incidence of treatment-emergent adverse events. Secondary and exploratory endpoints include PRKAG2 mRNA reduction, siRNA tissue concentrations and plasma pharmacokinetics.